Drugs / N. lactamica
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03630250 | Oct 2018 → Sep 2019 | bacterial meningitis, meningococcal infection | University of Southampton | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N. lactamica | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03630250 ↗ |
| Known as | Neisseria lactamica | “Neisseria lactamica is a commensal organism found in the human nasopharynx and is closely related to the pathogen N. meningitidis (meningococcus).” PMID 31048443 ↗ May 2019 |
| Modality | Other / unclassified | “using a genetically modified strain of N. lactamica that expresses the meningococcal antigen NadA” PMID 31048443 ↗ May 2019 |
| Route | Intranasal | “will receive an intranasal inoculation of either the NadA containing strain of N. lactamica” PMID 31048443 ↗ May 2019 |